Overview
SpectrumAi builds a digital platform for Applied Behavior Analysis (ABA) therapy used by clinicians and managed by providers and payers. Its tools include data collection and management for therapy sessions, data analytics, and artificial intelligence insights to track treatment progress and outcomes. How it works: clinicians enter and organize client data in the platform; analytics surface progress signals and guidance to help tailor therapy, while standard workflows improve consistency. SpectrumAi differentiates itself by focusing on the B2B market for ABA providers and payers, combining clinical workflow tools with payer-facing analytics to inform reimbursement decisions and measure value. Its goal is to raise the quality and consistency of autism care by using data-driven, standardized methods to improve therapy effectiveness and support decision-making across providers and payers.
Work here?Claim your company
Simplify's take
What believers are saying
- CentralReach updated Ling Shao's role on November 6, 2026, showing continued leadership relevance.
- SpectrumAi's 2026 site still markets Twyll, Patterns, and employer views to payors.
- The 2023 $20 million Series A from CVS Health Ventures funded product development and expansion.
What critics are saying
- CentralReach absorbed SpectrumAi in August 2025, ending its independent employer identity.
- Integration into Care360 can bury SpectrumAi's roadmap beneath CentralReach priorities by 2026.
- ABA value-based contracting depends on skeptical payors; weak outcomes evidence kills adoption quickly.
What makes SpectrumAi unique
- August 2025 acquisition by CentralReach folded SpectrumAi into Care360 outcomes-based care.
- Twyll captures in-session ABA data; Patterns turns it into payor-facing analytics.
- Ling Shao and Dr. Thomas Frazier give SpectrumAi rare autism-care product and clinical credibility.
Help us improve and share your feedback! Did you find this helpful?